Smith & Nephew PLC

SNN-N

Analysis and Opinions about SNN-N

Signal
Opinion
Expert
COMMENT
COMMENT
September 6, 2019

US Healthcare For knee replacements and implants he likes SNN-N. He does not prefer the ETFs, such as XLV-N, because they hold too broad of an array of companies, including the big drug companies that are under pressure. He would focus on the tool and device space instead.

Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
September 6, 2019

US Healthcare For knee replacements and implants he likes SNN-N. He does not prefer the ETFs, such as XLV-N, because they hold too broad of an array of companies, including the big drug companies that are under pressure. He would focus on the tool and device space instead.

HOLD
HOLD
July 17, 2019
They're a UK medical technology company, 75% in hips and knees. They had hiccups a year ago in their wound management business, but have subsided. He has owned this. He doesn't own it now, because the options market isn't very liquid in the U.S. Also, Stryker is the leader in robotics, and SNN is only second or third, launching in 2021. SNN has similar growth to Stryker. Good to hold.
Show full opinionHide full opinion
They're a UK medical technology company, 75% in hips and knees. They had hiccups a year ago in their wound management business, but have subsided. He has owned this. He doesn't own it now, because the options market isn't very liquid in the U.S. Also, Stryker is the leader in robotics, and SNN is only second or third, launching in 2021. SNN has similar growth to Stryker. Good to hold.
COMMENT
COMMENT
June 21, 2019
Have turned the business around and are starting to grow. Not a lot of debt, ROC is more than 10%. Dividend not growing a lot. He owns Stryker instead. Middle of the road in its sector. Not a leader.
Show full opinionHide full opinion
Have turned the business around and are starting to grow. Not a lot of debt, ROC is more than 10%. Dividend not growing a lot. He owns Stryker instead. Middle of the road in its sector. Not a leader.
COMMENT
COMMENT
July 5, 2018

Has owned it in the past. Primary business in orthopedics. Great company. Last quarter has been mixed. There is speculation that they are buying Boston Scientific. Valuation wise it is OK. Stryker (SYK-N) is taking leadership in the orthopedic space. Longer term he prefers Stryker (SYK-N).

Show full opinionHide full opinion

Has owned it in the past. Primary business in orthopedics. Great company. Last quarter has been mixed. There is speculation that they are buying Boston Scientific. Valuation wise it is OK. Stryker (SYK-N) is taking leadership in the orthopedic space. Longer term he prefers Stryker (SYK-N).

DON'T BUY
DON'T BUY
March 21, 2018

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

Show full opinionHide full opinion

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

PAST TOP PICK
PAST TOP PICK
August 1, 2012

(A Top Pick Aug 11/11. Up 24.13%.) Demand for discretionary medical devices has been affected by the economy. Like many European companies, the valuations are quite low and can have further upside from here.

Show full opinionHide full opinion

(A Top Pick Aug 11/11. Up 24.13%.) Demand for discretionary medical devices has been affected by the economy. Like many European companies, the valuations are quite low and can have further upside from here.

PAST TOP PICK
PAST TOP PICK
February 2, 2012
(A Top Pick Feb 23/11. Down 10.95%.) Medical devices. Just reported strong numbers. Volumes in replacement knees has suffered because of the economy but still likes this long-term because of demographic tailwinds. Strong possibility it will get taken out in 3-4 years by one of its competitors.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
February 2, 2012
(A Top Pick Feb 23/11. Down 10.95%.) Medical devices. Just reported strong numbers. Volumes in replacement knees has suffered because of the economy but still likes this long-term because of demographic tailwinds. Strong possibility it will get taken out in 3-4 years by one of its competitors.
BUY
BUY
November 29, 2011
Wounds (bandages), arthroscopic surgery and orthopedics. They are the largest presence in Europe, which is hurting them. A lot of people have lost their healthcare coverage and is hurting the industry. Ultimately this stock will do well.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
November 29, 2011
Wounds (bandages), arthroscopic surgery and orthopedics. They are the largest presence in Europe, which is hurting them. A lot of people have lost their healthcare coverage and is hurting the industry. Ultimately this stock will do well.
PAST TOP PICK
PAST TOP PICK
November 22, 2011
(A Top Pick Nov 19/10. Down 2.76%.) Economic environment has taken some of the wind out of their sails but they'll come back.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
November 22, 2011
(A Top Pick Nov 19/10. Down 2.76%.) Economic environment has taken some of the wind out of their sails but they'll come back.
PAST TOP PICK
PAST TOP PICK
August 30, 2011
(Top Pick Nov 10/10, Up 2.12%) knee replacements, demographic play. Last year and a half have not been that robust because knee replacements are a little bit elective. There is a pent up demand for this kind of surgery. Some interest in the space from some of their competitors.
Show full opinionHide full opinion
(Top Pick Nov 10/10, Up 2.12%) knee replacements, demographic play. Last year and a half have not been that robust because knee replacements are a little bit elective. There is a pent up demand for this kind of surgery. Some interest in the space from some of their competitors.
TOP PICK
TOP PICK
August 11, 2011
(London Stock exchange.) Medical devices. This sort of business that can continue to grow a respective of the economy. Good price.
Show full opinionHide full opinion
(London Stock exchange.) Medical devices. This sort of business that can continue to grow a respective of the economy. Good price.
TOP PICK
TOP PICK
February 23, 2011
Medical device manufacturer for replacement hips and knees. Huge demographic area. Not particularly expensive at less than 15X earnings. Strong balance sheet. Could be a takeout candidate.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
February 23, 2011
Medical device manufacturer for replacement hips and knees. Huge demographic area. Not particularly expensive at less than 15X earnings. Strong balance sheet. Could be a takeout candidate.
PAST TOP PICK
PAST TOP PICK
February 11, 2011
(A Top Pick Jan 5/10. Up 16.75%.)
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
February 11, 2011
(A Top Pick Jan 5/10. Up 16.75%.)
PAST TOP PICK
PAST TOP PICK
November 29, 2010
(A Top Pick Dec 29/09. Down 7.58%.) Still a Buy.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
November 29, 2010
(A Top Pick Dec 29/09. Down 7.58%.) Still a Buy.
TOP PICK
TOP PICK
November 19, 2010
Valuation is closer to $60. Likes the demographics for hip and knee replacements. Took a bit of a dip through 2008-2009 as the economy contracted.
Show full opinionHide full opinion
Smith & Nephew PLC (SNN-N)
November 19, 2010
Valuation is closer to $60. Likes the demographics for hip and knee replacements. Took a bit of a dip through 2008-2009 as the economy contracted.
Showing 1 to 15 of 33 entries

Smith & Nephew PLC(SNN-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Smith & Nephew PLC is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Smith & Nephew PLC(SNN-N) Frequently Asked Questions

What is Smith & Nephew PLC stock symbol?

Smith & Nephew PLC is a American stock, trading under the symbol SNN-N on the New York Stock Exchange (SNN). It is usually referred to as NYSE:SNN or SNN-N

Is Smith & Nephew PLC a buy or a sell?

In the last year, 1 stock analyst published opinions about SNN-N. 0 analyst recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Smith & Nephew PLC.

Is Smith & Nephew PLC a good investment or a top pick?

Smith & Nephew PLC was recommended as a Top Pick by Darren Sissons on 2019-09-06. Read the latest stock experts ratings for Smith & Nephew PLC.

Why is Smith & Nephew PLC stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Smith & Nephew PLC worth watching?

In the last year, there was no coverage of Smith & Nephew PLC published on Stockchase.

What is Smith & Nephew PLC stock price?

On 2020-06-05, Smith & Nephew PLC (SNN-N) stock closed at a price of $44.24.